基于三维分析框架的医药科技成果转化政策研究  

Translational policy research on medical and pharmaceutical science outcomes based on three-dimensional analysis framework

作　　者：王宇 曹日昇[2] 陈家应[3] 李建清 Wang Yu;Cao Risheng;Chen Jiaying;Li Jianqing(Translational Medicine Institute,Nanjing Medical University,Nanjing 210029,China;The First Affiliated Hospital,Nanjing Medical University,Nanjing 210029,China;Health Policy Research Center,Nanjing Medical University,Nanjing 211166,China;College of Medical Administration,Nanjing Medical University,Nanjing 211166,China)

机构地区：[1]南京医科大学转化医学研究院,210029 [2]南京医科大学第一附属医院,210029 [3]南京医科大学卫生政策研究中心,211166 [4]南京医科大学医政学院,211166

出　　处：《中华医院管理杂志》2021年第1期47-51,共5页Chinese Journal of Hospital Administration

基　　金：江苏省软科学研究项目(BR2019051);南京医科大学哲学社会科学发展专项(2019ZSY020)。

摘　　要：目的从政策研究层面为促进医药科技成果转化提供参考建议。方法作者结合医药科技成果转化特点,以政策工具为主线,引入创新价值链和创新主体链构建三维分析框架,即政策工具维度(供应面、环境面、需求面),创新价值链维度(研究开发、临床研究与示范应用、商业产业化)和创新主体链维度(高校院所、医疗机构、企业、政府、第三方机构)。针对2015年至2019年国家出台的70份医药卫生科技成果转化政策,使用三维框架进行文本量化分析。结果环境面和供应面政策工具使用存在过溢,需求面相对缺失;临床研究与示范应用是创新价值链维度的政策投入薄弱环节;创新主体链维度中的医疗机构和第三方机构政策频数较弱。结论根据三维框架分析结果结合行业特点,提出应增强医药特色,激发医院与院校活力,加大临床研究投入等政策完善建议。Objective To provide references for encouraging translation of medical and pharmaceutical research outcomes from a policy perspective.Methods In view of characteristics of such translation and using policy tools,the authors introduced the innovation value chain and innovation entity chain to create a three-dimensional analysis framework.The three dimensions refer to policy tools(supply side,environment side and demand side),innovation value chain(research and development,clinical research and pilot application,and commercial industrialization),and innovation entity chain(colleges,medial institutions,enterprises,government,and third parties).A three-dimensional framework was introduced for textual quantitative analysis,centering on 70 policy documents on such translation released from 2015 to 2019.Results Excessiveness was found in the environment side and supply side policy tools usage,while the demand side was deficient relatively;clinical research and pilot applications constitute the policy support weakness in innovation value chain;policy frequency on medical institutions and third parties was weak in the innovation entity chain dimension.Conclusions Based on the three-dimensional framework analysis results and sector specifics,the paper proposed such policy recommendations as highlighting features of medical and pharmaceutical sector,activating incentives of hospitals and colleges,and expanding resources for clinical research.

关 键 词：科研管理 医药卫生 成果转化 政策工具 创新价值链 创新主体链 

分 类 号：R-05[医药卫生] G311[文化科学]